WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur contact

- Last updated on GMT

Pic:getty/markrubens
Pic:getty/markrubens

Related tags: Wuxi biologics, Singapore, CDMO

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

A new site will add 120,000L biomanufacturing capacity to WuXi Biologics' global network by 2026.

It is expected to employ 1,500 research, development and manufacturing staff when complete; adding significantly to the 10,000 people the company already employs worldwide.

The company says the Singapore site will become a ‘critical part’ of its global supply chain network: and follows recent investments made in the US, Ireland, Germany and China.

The center will also support WuXi Biologics' Global Dual Sourcing strategy – a strategy to ensure that customer projects can be fulfilled at multiple facilities globally and thus mitigate potential risks.

Dr. Chris Chen, CEO of WuXi Biologics, said, "Singapore has established itself as one of the most advanced pharmaceutical hubs in the world. As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics' investment in the new CRDMO center will enhance the sustainable growth and success of the Singapore biotech ecosystem and enable the global biologics industry with a more robust supply chain.

"With the support of EDB and our local partners in Singapore, WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide.”

WuXi Biologics' investment plan is supported by the Singapore Economic Development Board (EDB), which champions Singapore’s central Asian location, pro-business environment, infrastructure and innovation ecosystem. 

The pharmaceutical sector’s manufacturing output has tripled since 2000: with some $12bn worth of products produced for global markets a year.

Dr. Beh Swan Gin, Chairman of EDB, said: "The investments will establish Singapore as a significant node in the company's global research, development and manufacturing network. It is a testament to Singapore's position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups."

Related news

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars